Early Detection for Pancreatic Cancer

(PRECEDE Trial)

Recruiting at 67 trial locations

Overseen By Naveen Fawas, BS

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Arbor Research Collaborative for Health

Disqualifiers: No PDAC history, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

10000 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to discover the best ways to detect pancreatic cancer early, particularly in those at higher risk. It focuses on individuals with a family history of pancreatic cancer or specific genetic changes that increase risk. No treatment is involved; instead, participants assist researchers by sharing their health information and possibly providing a sample, such as blood or saliva. Suitable candidates might have two or more relatives with pancreatic cancer or carry certain genetic variants linked to higher cancer risk. Participants contribute to a database that aids in understanding and preventing this serious condition.

As an unphased study, this trial offers participants the chance to contribute to groundbreaking research that could lead to early detection strategies for pancreatic cancer.

Do I have to stop taking my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about the Pancreatic Cancer Early Detection Consortium because it focuses on improving early detection rather than introducing a new treatment. Unlike current options that primarily address advanced stages of pancreatic cancer through surgery, chemotherapy, or radiation, this initiative aims to identify the disease at an earlier, more treatable stage. By advancing early detection methods, researchers hope to significantly improve survival rates and outcomes for patients, potentially transforming the way pancreatic cancer is managed in the future.

Who Is on the Research Team?

Diane Simeone, MD

Principal Investigator

UC San Diego Moores Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

Cohort 1

2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.

2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Biosample Collection

Single or serial biosample collection every 6-12 months in defined high-risk groups

6-12 months

Follow-up

Participants are monitored for safety and effectiveness after biosample collection

6 years

What Are the Treatments Tested in This Trial?

Interventions

• None

Who Is Running the Clinical Trial?

Arbor Research Collaborative for Health

Lead Sponsor

Trials

21

Recruited

35,500+